Annovis Bio Inc SEC Filings

Annovis Bio (ANVS) launched a registered direct primary offering of 1,670,732 shares of common stock at $2.05 per share, with gross proceeds of $3,425,001. The company estimates net proceeds of approximately $3.3 million, and the fee table shows proceeds to the company of $3,339,251 before expenses and fees. Annovis is also issuing placement agent warrants to purchase up to 83,537 shares at an exercise price of $2.5625 per share, exercisable for five years, and this supplement covers the common stock issuable upon their exercise.

H.C. Wainwright & Co. acted as exclusive placement agent. A 7.0% cash fee applies only to 597,561 shares, totaling $85,750. Shares outstanding were 24,443,938 as of October 24, 2025, and are expected to be 26,114,670 after the offering. Annovis plans to use proceeds to advance a Phase 3 study of Buntanetap in Alzheimer’s disease and for working capital and general corporate purposes.

Annovis Bio (ANVS) announced a registered direct offering, agreeing to sell 3,150,000 shares of common stock at $1.50 per share and pre-funded warrants to purchase up to 850,000 shares at $1.4999 (with a $0.0001 exercise price). The company expects gross proceeds of approximately $6.0 million, before fees and expenses. The transaction is expected to close on or about October 14, 2025, after customary conditions.

The company plans to use net proceeds to continue clinical development of its lead compound Buntanetap in a Phase 3 Alzheimer’s study and for working capital and general corporate purposes. Annovis agreed for one year not to enter into Variable Rate Transactions, subject to exceptions, and obtained 45‑day lock-ups from directors and officers. The placement agent will receive a 7% cash fee, up to $50,000 for counsel plus $10,000 clearing expenses, and warrants to purchase 200,000 shares at $2.20, exercisable immediately for five years. The securities are offered under an effective Form S-3 and a prospectus supplement dated October 10, 2025.

Annovis Bio (ANVS) launched a registered direct offering of 3,150,000 shares of common stock at $1.50 per share and pre-funded warrants to purchase up to 850,000 shares at $1.4999, each pre-funded warrant carrying a $0.0001 exercise price. The company is also registering placement agent warrants to purchase up to 200,000 shares at $2.20.

Gross proceeds are listed at $5,999,915 with a 7.0% placement fee; estimated net proceeds are approximately $5,515,000, to fund a Phase 3 Alzheimer’s study of Buntanetap and for working capital. The pre-funded warrants are immediately exercisable and include a beneficial ownership cap of 4.99%, or 9.99% at the purchaser’s election. Shares outstanding would be 24,152,377 after the offering, assuming full exercise of pre-funded warrants and no exercise of placement agent warrants, based on 20,152,377 shares as of October 10, 2025.

H.C. Wainwright & Co. served as exclusive placement agent. Annovis notes prior clinical results in Parkinson’s and Alzheimer’s studies and alignment with the FDA on an AD Phase 3 program while highlighting ongoing capital needs.

Michael B. Hoffman, a director of Annovis Bio, Inc. (ANVS), reported purchases of company common stock on 08/29/2025. He acquired three blocks of 5,000 shares each at prices of $2.28, $2.29, and $2.30, increasing his direct holdings from 1,469,929 to 1,479,929 shares. The filing also discloses indirect beneficial ownership of 223,357 shares held in the 2018 Jane and Michael Hoffman Descendants Trust, over which he has voting and investment power. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.

Michael B. Hoffman, a director of Annovis Bio, Inc. (ANVS), reported multiple open-market purchases of common stock on 08/19/2025. The Form 4 shows four acquisitions totaling 18,645 shares at prices ranging from $2.57 to $2.60, recorded as purchases (code A). After these transactions Mr. Hoffman directly beneficially owned 1,464,929 shares, and 223,357 shares were held indirectly in the 2018 Jane and Michael Hoffman Descendants Trust, over which he has voting and investment power.

The filing was signed by an attorney-in-fact on 08/20/2025. The form identifies Mr. Hoffman as a director and a single reporting person for this report.

Annovis Bio reported a cash balance of $17.1 million as of June 30, 2025 and a six-month net loss of $11.8 million, leaving an accumulated deficit of $146.6 million. Operating loss for the six months was $12.6 million versus $15.6 million in the prior year period. Net proceeds of $19.3 million were generated from a February 2025 underwritten offering with ThinkEquity, and the company sold an additional $0.5 million of common stock under its December 2024 ATM during the six months.

The filing discloses that management has concluded substantial doubt exists about the company’s ability to continue as a going concern and is pursuing additional capital through equity or debt financings, collaborations or cost deferrals. On the clinical front, Annovis initiated its FDA-cleared pivotal ANVS-25001 Phase 3 trial in early Alzheimer’s disease in February 2025 and describes prior topline PD and AD data and alignment with the FDA on a development path for buntanetap.

Annovis Bio, Inc. furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. The filing indicates the press release is included as Exhibit 99.1 and also includes the Cover Page Interactive Data File as Exhibit 104. The registrant is identified as an emerging growth company and has elected not to use the extended transition period for new or revised accounting standards.

The 8-K text itself does not present the numerical results or additional operational details; those items are contained in the referenced press release furnished as an exhibit.